AAVXF
ABIVAX Société Anonyme
Price Chart
Latest Quote
$120.85
Current Price| Previous Close | $120.85 |
| Open | $120.85 |
| Day High | $120.85 |
| Day Low | $120.85 |
| Volume | 100 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 78.44M |
| Total Debt | $87.35M |
| Cash Equivalents | $696.23M |
| Revenue | $6.27M |
| Net Income | $-346.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.48B |
| EPS (TTM) | $-5.32 |
| Exchange | PNK |
📊 Custom Metrics & Score
Score: 14/42| Debt to Equity | 2.40 |
| Debt to Earnings | -0.55 |
| Current Ratio | 1.84 |
| Quick Ratio | 1.72 |
| Return on Equity | -434.26% |
| Avg FCF Growth | 60.77% |
| FCF Yield | -1.63% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-01-30 | $120.85 | 0 |
| 2026-01-29 | $120.85 | 0 |
| 2026-01-28 | $120.85 | 0 |
| 2026-01-27 | $120.85 | 0 |
| 2026-01-26 | $120.85 | 0 |
| 2026-01-23 | $120.85 | 0 |
| 2026-01-22 | $120.85 | 0 |
| 2026-01-21 | $120.85 | 0 |
| 2026-01-20 | $120.85 | 0 |
| 2026-01-16 | $120.85 | 0 |
| 2026-01-15 | $120.85 | 100 |
| 2026-01-14 | $120.66 | 200 |
| 2026-01-13 | $114.86 | 300 |
| 2026-01-12 | $123.00 | 500 |
| 2026-01-09 | $119.10 | 0 |
| 2026-01-08 | $119.10 | 100 |
| 2026-01-07 | $124.40 | 0 |
| 2026-01-06 | $124.40 | 0 |
| 2026-01-05 | $124.40 | 100 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
📰 Latest News
ABIVAX Société Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs
Insider Monkey • 2026-02-02T09:16:52Z
Better Long-Term Buy: This Emerging Player or the Industry Leader?
Motley Fool • 2026-01-30T20:50:00Z
Sector Update: Health Care Stocks Decline Late Afternoon
MT Newswires • 2026-01-20T20:57:00ZPrediction: This Healthcare Stock Could Soar by 72% in 2026
Motley Fool • 2026-01-19T21:05:00Z
Has Abivax (ENXTPA:ABVX) Risen Too Far After Increased Biotech Pipeline Attention?
Simply Wall St. • 2026-01-17T12:10:28Z
JPM26: Day 1 – drug prices and policy changes drive the agenda
Pharmaceutical Technology • 2026-01-13T10:59:17Z
Stocks to Watch Monday Recap: Capital One, UnitedHealth, Walmart, Exxon
The Wall Street Journal • 2026-01-12T19:32:09Z
This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest.
Barrons.com • 2026-01-12T18:20:00Z
JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax
Pharmaceutical Technology • 2026-01-12T16:17:34Z
Abivax shares surge after report flags continued Eli Lilly takeover interest
Investing.com • 2026-01-12T11:14:00ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | $50,526,000 | $45,517,000 |
| Cost Of Revenue | - | - | $50,764,000 | $45,517,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $12,431,000 | $13,826,000 | $6,940,000 | $3,558,000 |
| Total Expenses | $172,984,000 | $127,377,000 | $51,205,000 | $41,398,000 |
| Other Income Expense | $2,674,000 | $-10,852,000 | $-4,266,000 | $2,425,000 |
| Other Non Operating Income Expenses | $-1,367,000 | $3,198,000 | $1,446,000 | - |
| Net Non Operating Interest Income Expense | $-5,931,000 | $-9,510,000 | $-5,271,000 | $-3,476,000 |
| Total Other Finance Cost | $2,456,000 | $-1,543,000 | $-1,669,000 | $-82,000 |
| Interest Expense Non Operating | $12,431,000 | $13,826,000 | $6,940,000 | $3,558,000 |
| Operating Expense | $172,984,000 | $127,377,000 | $51,205,000 | $41,398,000 |
| Other Operating Expenses | $-12,448,000 | $-4,621,000 | $-4,583,000 | $-11,962,000 |
| Selling And Marketing Expense | $932,000 | $709,000 | $0 | $0 |
| General And Administrative Expense | $37,968,000 | $28,113,000 | $7,493,000 | $5,579,000 |
| Rent Expense Supplemental | - | - | $1,048,000 | $548,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Net Interest Income | $-5,931,000 | $-9,510,000 | $-5,271,000 | $-3,476,000 |
| Interest Income | $8,956,000 | $2,773,000 | $0 | $0 |
| Normalized Income | $-178,916,000 | $-136,888,000 | $-56,474,000 | $-44,877,000 |
| Net Income From Continuing And Discontinued Operation | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Total Operating Income As Reported | $-172,984,000 | $-127,376,000 | $-64,836,000 | $-41,400,000 |
| Net Income Common Stockholders | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Net Income | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Net Income Including Noncontrolling Interests | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Net Income Continuous Operations | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Pretax Income | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Special Income Charges | $0 | $-3,239,000 | $-13,632,000 | $0 |
| Interest Income Non Operating | $8,956,000 | $2,773,000 | $0 | $0 |
| Operating Income | $-172,984,000 | $-127,377,000 | $-51,205,000 | $-41,398,000 |
| Depreciation Amortization Depletion Income Statement | - | - | $71,000 | $156,000 |
| Depreciation And Amortization In Income Statement | - | - | $71,000 | $156,000 |
| Depreciation Income Statement | - | - | $71,000 | $156,000 |
| Gross Profit | - | - | $-50,764,000 | $-45,517,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.80 | $-3.43 | $-3.18 | $-2.75 |
| Basic EPS | $-2.80 | $-3.43 | $-3.18 | $-2.75 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-165,385,000 | $-122,355,000 | $-49,049,000 | $-41,017,000 |
| Total Unusual Items | $2,674,000 | $-10,852,000 | $-4,266,000 | $2,425,000 |
| Total Unusual Items Excluding Goodwill | $2,674,000 | $-10,852,000 | $-4,266,000 | $2,425,000 |
| Reconciled Depreciation | $1,100,000 | $707,000 | $485,000 | $302,000 |
| EBITDA (Bullshit earnings) | $-162,711,000 | $-133,207,000 | $-53,315,000 | $-38,592,000 |
| EBIT | $-163,811,000 | $-133,914,000 | $-53,800,000 | $-38,894,000 |
| Diluted Average Shares | $63,046,350 | $43,066,012 | $19,092,442 | $15,455,991 |
| Basic Average Shares | $63,046,350 | $43,066,012 | $19,092,442 | $15,455,991 |
| Diluted NI Availto Com Stockholders | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $0 | $13,632,000 | $0 |
| Restructuring And Mergern Acquisition | $1,367,000 | $-3,198,000 | $-1,446,000 | $0 |
| Gain On Sale Of Security | $2,674,000 | $-7,613,000 | $9,366,000 | $2,425,000 |
| Research And Development | $146,532,000 | $103,176,000 | $48,295,000 | $47,781,000 |
| Selling General And Administration | $38,900,000 | $28,822,000 | $7,493,000 | $5,579,000 |
| Other Gand A | $16,211,000 | $13,298,000 | $6,090,000 | $3,259,000 |
| Salaries And Wages | $21,757,000 | $14,815,000 | $1,403,000 | $2,320,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $0 | $0 |
| Other Special Charges | - | $3,239,000 | $13,870,000 | $-125,000 |
| Other Taxes | - | - | $44,000 | $116,000 |
| Rent And Landing Fees | - | - | $1,048,000 | $548,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $15,559,000 | $170,987,000 | $-17,837,000 | $-6,164,000 |
| Total Assets | $205,228,000 | $327,062,000 | $75,544,000 | $109,230,000 |
| Total Non Current Assets | $34,558,000 | $41,090,000 | $39,363,000 | $33,745,000 |
| Other Non Current Assets | $950,000 | $2,320,000 | $1,036,000 | $1,000 |
| Non Current Prepaid Assets | $5,792,000 | $12,746,000 | $11,709,000 | $1,342,000 |
| Investmentin Financial Assets | $126,000 | $124,000 | $0 | $0 |
| Goodwill And Other Intangible Assets | $25,025,000 | $25,023,000 | $25,026,000 | $32,097,000 |
| Other Intangible Assets | $6,606,000 | $6,604,000 | $6,607,000 | $92,000 |
| Current Assets | $170,671,000 | $285,972,000 | $36,181,000 | $75,485,000 |
| Prepaid Assets | $10,787,000 | $5,882,000 | $915,000 | $6,446,000 |
| Receivables | $15,663,000 | $19,099,000 | $8,316,000 | $8,339,000 |
| Taxes Receivable | $15,615,000 | $19,039,000 | $8,062,000 | $8,335,000 |
| Notes Receivable | $48,000 | $60,000 | $254,000 | $4,000 |
| Cash Cash Equivalents And Short Term Investments | $144,221,000 | $260,992,000 | $26,950,000 | $60,701,000 |
| Cash And Cash Equivalents | $144,221,000 | $251,942,000 | $26,950,000 | $60,701,000 |
| Cash Equivalents | $56,956,000 | $233,837,000 | $26,944,000 | $6,000 |
| Cash Financial | $87,265,000 | $18,105,000 | $6,000 | $60,695,000 |
| Non Current Deferred Assets | - | $2,320,000 | $1,037,000 | $0 |
| Other Current Assets | - | $-1,000 | - | $-1,000 |
| Current Deferred Assets | - | $5,746,000 | $915,000 | $721,000 |
| Other Receivables | - | $60,000 | $254,000 | $4,000 |
| Non Current Note Receivables | - | - | $1,238,000 | $2,742,000 |
| Inventory | - | - | - | $4,000,000 |
| Accounts Receivable | - | - | - | $1,472,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $97,361,000 | $58,044,000 | $39,161,000 | $44,881,000 |
| Long Term Debt And Capital Lease Obligation | $53,592,000 | $26,784,000 | $9,127,000 | $34,649,000 |
| Long Term Debt | $52,161,000 | $26,624,000 | $8,288,000 | $34,606,000 |
| Current Debt And Capital Lease Obligation | $43,769,000 | $31,260,000 | $30,034,000 | $10,232,000 |
| Current Debt | $42,837,000 | $30,881,000 | $29,489,000 | $10,062,000 |
| Other Current Borrowings | $42,837,000 | $30,881,000 | $29,489,000 | $10,062,000 |
| Net Debt | - | - | $10,827,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $164,644,000 | $131,052,000 | $68,355,000 | $83,297,000 |
| Total Non Current Liabilities Net Minority Interest | $71,810,000 | $42,937,000 | $16,892,000 | $51,033,000 |
| Other Non Current Liabilities | $13,023,000 | $15,494,000 | $6,549,000 | $5,661,000 |
| Derivative Product Liabilities | $3,620,000 | $0 | $566,000 | $9,932,000 |
| Current Liabilities | $92,834,000 | $88,115,000 | $51,463,000 | $32,264,000 |
| Current Deferred Liabilities | $0 | $52,000 | $133,000 | $162,000 |
| Payables And Accrued Expenses | $48,533,000 | $53,294,000 | $17,775,000 | $20,758,000 |
| Payables | $48,533,000 | $53,294,000 | $17,775,000 | $20,758,000 |
| Total Tax Payable | $4,709,000 | $6,073,000 | $2,300,000 | $2,200,000 |
| Accounts Payable | $43,824,000 | $47,221,000 | $15,475,000 | $18,558,000 |
| Other Current Liabilities | - | $3,509,000 | $3,521,000 | $1,112,000 |
| Other Payable | - | $3,694,000 | $1,348,000 | $1,180,000 |
| Interest Payable | - | - | $655,000 | $652,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $40,584,000 | $196,010,000 | $7,189,000 | $25,933,000 |
| Total Equity Gross Minority Interest | $40,584,000 | $196,010,000 | $7,189,000 | $25,933,000 |
| Stockholders Equity | $40,584,000 | $196,010,000 | $7,189,000 | $25,933,000 |
| Gains Losses Not Affecting Retained Earnings | $-75,000 | $112,000 | $0 | $0 |
| Retained Earnings | $-438,879,000 | $-282,949,000 | $-143,510,000 | $-81,813,000 |
| Other Equity Interest | - | - | $6,819,000 | $6,837,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $63,347,837 | $62,917,479 | $22,301,185 | $16,755,451 |
| Share Issued | $63,347,837 | $62,928,818 | $22,301,185 | $16,755,451 |
| Tangible Book Value | $15,559,000 | $170,987,000 | $-17,837,000 | $-6,164,000 |
| Invested Capital | $135,582,000 | $253,515,000 | $44,966,000 | $70,601,000 |
| Working Capital | $77,837,000 | $197,857,000 | $-15,282,000 | $43,221,000 |
| Capital Lease Obligations | $2,363,000 | $539,000 | $1,384,000 | $213,000 |
| Total Capitalization | $92,745,000 | $222,634,000 | $15,477,000 | $60,539,000 |
| Foreign Currency Translation Adjustments | $-75,000 | $112,000 | $0 | - |
| Additional Paid In Capital | $478,905,000 | $478,218,000 | $150,476,000 | $107,578,000 |
| Capital Stock | $633,000 | $629,000 | $223,000 | $168,000 |
| Common Stock | $633,000 | $629,000 | $223,000 | $168,000 |
| Employee Benefits | $756,000 | $629,000 | $610,000 | $693,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $756,000 | $629,000 | $610,000 | $693,000 |
| Long Term Capital Lease Obligation | $1,431,000 | $160,000 | $839,000 | $43,000 |
| Long Term Provisions | $819,000 | $30,000 | $40,000 | $98,000 |
| Current Deferred Revenue | $0 | $52,000 | $133,000 | $162,000 |
| Current Capital Lease Obligation | $932,000 | $379,000 | $545,000 | $170,000 |
| Current Provisions | $532,000 | - | - | $157,000 |
| Investments And Advances | $126,000 | $124,000 | $0 | $0 |
| Available For Sale Securities | $126,000 | $124,000 | $77,000 | $220,000 |
| Goodwill | $18,419,000 | $18,419,000 | $18,419,000 | $32,005,000 |
| Net PPE | $2,665,000 | $877,000 | $1,592,000 | $305,000 |
| Accumulated Depreciation | $-1,364,000 | $-1,489,000 | $-808,000 | $-925,000 |
| Gross PPE | $4,029,000 | $2,366,000 | $2,400,000 | $1,230,000 |
| Other Properties | $513,000 | $513,000 | $436,000 | $402,000 |
| Machinery Furniture Equipment | $698,000 | $507,000 | $346,000 | $235,000 |
| Buildings And Improvements | $2,818,000 | $1,346,000 | $1,618,000 | $593,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $9,050,000 | $0 | $0 |
| Treasury Shares Number | - | $11,339 | $12,000 | $8,600 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | $1,155,000 | $538,000 |
| Current Accrued Expenses | - | - | $655,000 | $1,497,000 |
| Construction In Progress | - | - | $67,000 | $10,000 |
| Work In Process | - | - | - | $4,000,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-154,715,000 | $-97,395,000 | $-54,259,000 | $-45,095,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-154,072,000 | $-97,130,000 | $-53,936,000 | $-45,048,000 |
| Cash Flow From Continuing Operating Activities | $-154,073,000 | $-97,130,000 | $-53,933,000 | $-45,050,000 |
| Operating Gains Losses | $1,474,000 | $-1,083,000 | $-10,782,000 | $-2,310,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-643,000 | $-265,000 | $-323,000 | $-47,000 |
| Investing Cash Flow | $15,762,000 | $-8,095,000 | $-12,026,000 | $-6,232,000 |
| Cash Flow From Continuing Investing Activities | $15,763,000 | $-8,095,000 | $-12,026,000 | $-6,232,000 |
| Net Other Investing Changes | $8,227,000 | $-10,230,000 | $-8,809,000 | $-4,000,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $434,000 | $353,387,000 | $46,374,000 | $69,683,000 |
| Financing Cash Flow | $28,207,000 | $335,290,000 | $32,211,000 | $82,679,000 |
| Cash Flow From Continuing Financing Activities | $28,207,000 | $335,289,000 | $32,212,000 | $82,679,000 |
| Net Other Financing Charges | $-2,017,000 | $-28,057,000 | $-437,000 | $-4,223,000 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $434,000 | $353,387,000 | $46,374,000 | $69,683,000 |
| Common Stock Issuance | $434,000 | $353,387,000 | $46,374,000 | $69,683,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-10,458,000 | $-40,602,000 | $-9,711,000 | $-5,786,000 |
| Issuance Of Debt | $47,944,000 | $55,841,000 | $0 | $24,913,000 |
| End Cash Position | $144,221,000 | $251,942,000 | $26,950,000 | $60,701,000 |
| Beginning Cash Position | $251,942,000 | $26,950,000 | $60,701,000 | $29,302,000 |
| Effect Of Exchange Rate Changes | $2,382,000 | $-5,072,000 | $0 | $0 |
| Changes In Cash | $-110,103,000 | $230,064,000 | $-33,751,000 | $31,399,000 |
| Interest Paid Cff | $-7,696,000 | $-5,279,000 | $-4,015,000 | $-1,908,000 |
| Net Issuance Payments Of Debt | $37,486,000 | $15,239,000 | $-9,711,000 | $19,127,000 |
| Net Long Term Debt Issuance | $37,486,000 | $15,239,000 | $-9,711,000 | $19,127,000 |
| Long Term Debt Payments | $-10,458,000 | $-40,602,000 | $-9,711,000 | $-5,786,000 |
| Long Term Debt Issuance | $47,944,000 | $55,841,000 | $0 | $24,913,000 |
| Interest Received Cfi | $8,178,000 | $2,400,000 | $19,000 | $0 |
| Net Business Purchase And Sale | $0 | $0 | $-2,913,000 | $-2,176,000 |
| Purchase Of Business | $0 | $0 | $-2,913,000 | $-2,176,000 |
| Net Intangibles Purchase And Sale | $-3,000 | $0 | $-35,000 | $0 |
| Purchase Of Intangibles | $-3,000 | $0 | $-35,000 | $0 |
| Net PPE Purchase And Sale | $-640,000 | $-265,000 | $-288,000 | $-47,000 |
| Purchase Of PPE | $-640,000 | $-265,000 | $-288,000 | $-47,000 |
| Change In Working Capital | $1,423,000 | $21,266,000 | $-2,002,000 | $-668,000 |
| Change In Other Working Capital | $1,763,000 | $-81,000 | $-26,000 | $-41,000 |
| Change In Payables And Accrued Expense | $-4,931,000 | $35,578,000 | $-2,288,000 | $1,350,000 |
| Change In Payable | $-4,931,000 | $35,578,000 | $-2,288,000 | $1,350,000 |
| Change In Account Payable | $-3,444,000 | $31,757,000 | $-2,388,000 | $1,141,000 |
| Change In Tax Payable | $-1,487,000 | $3,821,000 | $100,000 | $209,000 |
| Change In Income Tax Payable | $-1,487,000 | $3,821,000 | $100,000 | $209,000 |
| Change In Receivables | $4,591,000 | $-14,231,000 | $312,000 | $-1,977,000 |
| Other Non Cash Items | $-2,051,000 | $21,541,000 | $6,635,000 | $-748,000 |
| Stock Based Compensation | $20,224,000 | $8,179,000 | $-1,164,000 | $828,000 |
| Asset Impairment Charge | $0 | $0 | $13,632,000 | $0 |
| Depreciation Amortization Depletion | $1,100,000 | $707,000 | $485,000 | $302,000 |
| Depreciation And Amortization | $1,100,000 | $707,000 | $485,000 | $302,000 |
| Pension And Employee Benefit Expense | $74,000 | $109,000 | $143,000 | $117,000 |
| Gain Loss On Investment Securities | $1,400,000 | $-1,192,000 | $-10,925,000 | $-2,427,000 |
| Net Income From Continuing Operations | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 |
| Other Cash Adjustment Outside Changein Cash | - | $-1,000 | $-3,000 | - |
| Proceeds From Stock Option Exercised | - | $3,000 | $3,000 | $0 |
| Net Investment Purchase And Sale | - | $-8,610,000 | $-470,000 | $-9,000 |
| Sale Of Investment | - | $741,000 | $218,000 | $0 |
| Purchase Of Investment | - | $-9,351,000 | $-470,000 | $-9,000 |
| Change In Other Current Assets | - | $3,740,000 | $-32,000 | $168,000 |
| Amortization Cash Flow | - | $0 | $309,000 | $156,000 |
| Amortization Of Intangibles | - | $0 | $309,000 | $156,000 |
| Depreciation | - | $708,000 | - | - |
| Net Foreign Currency Exchange Gain Loss | - | $5,573,000 | $0 | $0 |
| Sale Of PPE | - | - | - | $312,000 |
| Taxes Refund Paid | - | - | - | $0 |
| Interest Received Cfo | - | - | - | $82,000 |
| Interest Paid Cfo | - | - | - | $-1,922,000 |
| Change In Other Current Liabilities | - | - | - | $1,143,000 |
| Changes In Account Receivables | - | - | - | $-4,000,000 |